跳至主要内容
临床试验/NCT06332196
NCT06332196Unknown不适用

Immunodeficiency and Cancer: Identification of Congenital Immune System Defects Underlying Paediatric Lymphomas

Meyer Children's Hospital IRCCS4 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2023年10月18日最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
入组人数
50
试验地点
4
主要终点
To unravel inborn error of immunity behind Lymphoid neoplasm in children

研究概览

简要总结

Inborn Errors of Immunity (IEI) are a heterogeneous group of disorders characterised not only by an infectious diathesis, but by a wide variety of other clinical manifestations. Lymphoma is one of the most common malignancies in children and may be the first clinical manifestation of IEI, thereby 'hiding' the immune defect and delaying genetic/immunological diagnosis. Lymphomas, especially non-Hodgkin's lymphomas (NHL) are frequently associated with congenital defects of the immune system, in particular diffuse large B-cell lymphoma and Burkitt's lymphoma. Preliminary analyses conducted on 6 patients diagnosed with NHL allowed the identification of genetic variants in genes associated with IEI. In clinical practice, the diagnosis and choice of therapeutic treatment in patients with immunodeficiency-associated lymphoma are decisive and, due to the complex pathophysiology of the disease, it is not always possible to identify the boundary between benign and malignant proliferation. The identification of an undiagnosed immunodeficiency in patients with lymphoma will ensure the opportunity to apply targeted therapies, such as allogeneic haematopoietic stem cell transplantation, instead of standard clinical management based mainly on chemotherapy. The study aims to identify possible congenital defects of immunity, i.e. genetic disorders affecting the immune system, as responsible for the development of haematological malignancies. Through a multidisciplinary approach involving immunological analyses, genetic analyses and a thorough examination of clinical manifestations, we aim to characterise the immunological component underlying the development of paediatric lymphomas.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
1 Day 至 24 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with a clinical diagnosis of Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NEIL) with or without signs of immune dysregulation (lymphoproliferation, autoimmunity, hypogammaglobulinaemia, family history of immunodeficiency).
  • Patients with previous HL or NEIL lymphoma who have developed, concomitantly with the tumour or subsequently, clinical manifestations mentioned above attributable to a congenital defect of immunity.

排除标准

  • Patients with known genetic diseases, or who do not consent to participate in the study

研究组 & 干预措施

Patient with Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NEIL)

Other

Patient with Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NEIL)

干预措施: Analysis of biological sample and clinical data (Other)

结局指标

主要结局

To unravel inborn error of immunity behind Lymphoid neoplasm in children

时间窗: Through study completion, an average of 1 year

Characterizing the role of the immune system in the pathogenesis of polyclonal and clonal lymphoproliferation. In particular, the main aim of our study will be the identification, by means of second-generation genetic analysis and functional validation studies of the identified variants, of congenital immune system defects in patients with lymphoid neoplasia

次要结局

  • Identification of lymphoma-specific biomarkers(Through study completion, an average of 1 year)

研究者

发起方
Meyer Children's Hospital IRCCS
申办方类型
Other
责任方
Principal Investigator
主要研究者

Eleonora Gambineri

Principal Investigator

Meyer Children's Hospital IRCCS

研究点 (4)

Loading locations...

相似试验